FARGO, N.D. (September 11, 2023) – Jennifer Meade has been named President of Aldevron, effective September 11th 2023, as part of a planned leadership transition. She replaces Kevin Ballinger, who has departed Aldevron after leading the organization for three years.
Michael Chambers, the founding CEO of Aldevron, has been elected to the board of directors for the Whitehead Institute at the Massachusetts Institute of Technology.
Danaher Corporation (NYSE: DHR) announced today that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper. View Danaher's full press release on their website.
The Joint Session of the State of North Dakota’s 67th Legislative Assembly held its opening sessions earlier this week, and featured Governor Doug Burgum’s 2021 State of the State address. Burgum reflected on the progress and challenges of the past year, calling for bold action and investments in infrastructure and other priorities to position the state for a bright future.
Aldevron today announced it ranked 287 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26th year. Aldevron’s growth surpassed all expectations during this period.
The Technology Council of North Dakota (TechND) named Aldevron one of three leading businesses within the technology sector, emphasizing its achievements and contributions to the biotech industry through innovation and expertise.
Aldevron, a leading manufacturer of plasmid DNA, proteins and mRNA, today announced the sale of its Germany based antibody discovery business. Brian Walters, current president of the business unit and longtime employee of Aldevron, led a group of investors to purchase the business for an undisclosed amount. The transaction is effective immediately.
A plasmid DNA manufacturer is planning to scale up its production capacity to meet the growing needs of gene therapy. Aldevron, a company based in North Dakota, expects to open a new 189,000 sq. ft facility in spring 2021 to add to their existing 70,000 sq. ft of manufacturing space.
Attracting one of med-tech’s most accomplished executives, Aldevron has named Kevin Ballinger as Chief Executive Officer, effective July 13, 2020. Aldevron’s co-founder, Michael Chambers, has been named Executive Chairman of the board. Chambers initiated the transition to allow him to focus on innovation, corporate strategy and working with clients and industry thought leaders to develop new technologies that enable genetic medicine. Ballinger will assume day-to-day operational leadership of Aldevron, facilitating the company’s rapid growth.
In June of 2019, Aldevron announced its massive 14-acre campus expansion. The construction began with a groundbreaking ceremony in August of 2019, launching the buildout of the campus’ second GMP manufacturing facility. This 189,000 square-foot, two-story building is slated to increase Aldevron’s GMP and GMP-Source production capacity up to 10 times its current output. In December of 2019, a major milestone was reached when structural steel beams were installed (pictured).
